Too many underestimate the effects of Covid-19 vaccines on event amplification in the control arm and the mitigating vaccine effect of V in the experimental arm of any current trial involving the cardio vascular system such as RESPECT, MITIGATE, or BRAVE.
The first to report will blow the top off IMO. I've always thought V would not receive wide spread recognition until there is more proof of broader inherent pleiotropic properties.
Once that genie's out... we'll see upgrades and 30.00/share in short order.
Market Data 
Markets 
AI
